Literature DB >> 23809356

Survival rate and prevalence of bronchopulmonary dysplasia in extremely low birth weight infants.

Giuseppe Latini1, Claudio De Felice, Raffaella Giannuzzi, Antonio Del Vecchio.   

Abstract

BACKGROUND: Bronchopulmonary dysplasia (BPD) continues to represent a significant cause of morbidity among survivors of severe prematurity in the NICU. The increasing prevalence of BPD over the decades has been suggested to be related to the increased survival of extremely low birthweight infants. AIMS: To evaluate differences in prevalence of BPD (BPD28d and BPD36wk) and as a function of survival rate in extremely low birth weight (ELBW) infants over time, and to explore its relationship with known associated risk factors.
METHODS: Survival rate and prevalence of oxygen-dependency =28 days (BPD28d) and oxygen-dependency =36 weeks postmenstrual age (BPD36wk) were evaluated in ELBW newborns (mean gestational age: 27.12.2 weeks; mean birth weight: 817142 g) consecutively admitted to the Brindisi NICU over the last 26 years. Two arbitrarily chosen time periods were compared: Period 1: July 1st, 1986 to June 30, 2002 vs. Period 2: July 1st, 2002 to December 31, 2012. Analyzed variables included gestational age, birth weight, intubation time, hours of O2 administration, NCPAP, and use of surfactant. Differences between the time periods were assessed by chi-square statistics, Fisher's tests or Mann-Whitney test, as appropriate. A two-tailed p value <0.05 was considered to indicate statistical significance.
RESULTS: Survival rate of ELBW infants over the examined time periods dramatically improved from 42.3% to 72.6% (p < 0.0001), whereas changes in the prevalence of BPD28d and BPD36wk were not statistically significant (30.5% vs. 39.3%, p = 0.2137 and 5.5% vs. 13.1%, p = 0.1452, respectively). Likewise, BPD severity was not significantly different between the two time periods (p = 0.1635). Gestational age and birth weight of surviving neonates did not significantly change between the two time periods (p = 0.8050 and p = 0.6986, respectively), whereas significantly increased intubation time (median values: 144 hours vs. 33 hours, p <0.0001) and use of exogenous surfactant (89.3% vs. 48.6%, p < 0.0001) was evidenced for the second time period, as well as NCPAP (median values: 600 hours vs. 377 hours, p = 0.0005). A statistically non-significant trend for a prolonged O2 administration in period 2 (p = 0.0850) was also observed.
CONCLUSION: Our findings indicate that a significantly increased survival is not necessarily associated with a significant difference in the prevalence of BPD among ELBW infants.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23809356     DOI: 10.1016/S0378-3782(13)70020-3

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  15 in total

1.  Assessment of early nutritional intake in preterm infants with bronchopulmonary dysplasia: a cohort study.

Authors:  Brunna G Milanesi; Paola At Lima; Letícia D Villela; Amanda S Martins; Saint Clair S Gomes-Junior; Maria E L Moreira; Maria Dalva Barbosa Baker Méio
Journal:  Eur J Pediatr       Date:  2021-01-03       Impact factor: 3.183

2.  Airway metabolome and chronic lung disease of prematurity.

Authors:  Deepa Rastogi; Judy L Aschner
Journal:  J Pediatr       Date:  2014-10-23       Impact factor: 4.406

3.  Prospective economic evaluation alongside the non-invasive ventilation trial.

Authors:  M E Mowitz; J A F Zupancic; D Millar; H Kirpalani; J S Gaulton; R S Roberts; W Mao; D Dukhovny
Journal:  J Perinatol       Date:  2016-09-29       Impact factor: 2.521

4.  The economic impact of prematurity and bronchopulmonary dysplasia.

Authors:  María Álvarez-Fuente; Luis Arruza; Marta Muro; Carlos Zozaya; Alejandro Avila; Paloma López-Ortego; Carmen González-Armengod; Alba Torrent; Jose Luis Gavilán; María Jesús Del Cerro
Journal:  Eur J Pediatr       Date:  2017-09-09       Impact factor: 3.183

Review 5.  Disrupted lung development and bronchopulmonary dysplasia: opportunities for lung repair and regeneration.

Authors:  Christopher D Baker; Cristina M Alvira
Journal:  Curr Opin Pediatr       Date:  2014-06       Impact factor: 2.856

6.  Cost-effectiveness Analysis of Screening Extremely Low Birth Weight Children for Hepatoblastoma Using Serum Alpha-fetoprotein.

Authors:  Rebecca MacDonell-Yilmaz; Kelly Anderson; Bradley DeNardo; Philippa Sprinz; William V Padula
Journal:  J Pediatr       Date:  2020-05-26       Impact factor: 4.406

7.  Neonatal mortality and morbidity among infants between 24 to 31 complete weeks: a multicenter survey in China from 2013 to 2014.

Authors:  XiangYong Kong; FengDan Xu; Rong Wu; Hui Wu; Rong Ju; XiaoLin Zhao; XiaoMei Tong; HongYan Lv; YanJie Ding; Fang Liu; Ping Xu; WeiPeng Liu; HongBin Cheng; TieQiang Chen; ShuJuan Zeng; WenZheng Jia; ZhanKui Li; HuiXian Qiu; Jin Wang; ZhiChun Feng
Journal:  BMC Pediatr       Date:  2016-11-03       Impact factor: 2.125

8.  Neurodevelopmental outcome of extremely low birth weight infants at 24 months corrected age: a comparison between Griffiths and Bayley Scales.

Authors:  Odoardo Picciolini; Chiara Squarza; Camilla Fontana; Maria Lorella Giannì; Ivan Cortinovis; Silvana Gangi; Laura Gardon; Gisella Presezzi; Monica Fumagalli; Fabio Mosca
Journal:  BMC Pediatr       Date:  2015-09-30       Impact factor: 2.125

9.  Learning Disabilities in Extremely Low Birth Weight Children and Neurodevelopmental Profiles at Preschool Age.

Authors:  Chiara Squarza; Odoardo Picciolini; Laura Gardon; Maria L Giannì; Alessandra Murru; Silvana Gangi; Ivan Cortinovis; Silvano Milani; Fabio Mosca
Journal:  Front Psychol       Date:  2016-06-28

10.  The Effect of Gender on Mesenchymal Stem Cell (MSC) Efficacy in Neonatal Hyperoxia-Induced Lung Injury.

Authors:  Ibrahim Sammour; Santhosh Somashekar; Jian Huang; Sunil Batlahally; Matthew Breton; Krystalenia Valasaki; Aisha Khan; Shu Wu; Karen C Young
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.